Lupin’s Neulasta Biosimilar Set For MENA With Axantia Deal

Pegfilgrastim Deal Follows Recent Arrangement In Brazil With Biomm

 
• By Dean Rudge

Awaiting USFDA action for its proposed biosimilar to Neulasta, Lupin has out-licensed rights for the product to another set of territories following a recent deal covering Brazil.

Earth
Lupin's latest deal for pegfilgrastim covers the MENA region • Source: Shutterstock

More from Biosimilars

More from Products